The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes.
The Inflammasomes are multi-protein complexes that regulate caspase-1 activation and the production of the pro-inflammatory cytokine IL-1β. Previous studies identified a class of diarylsulfonylurea containing compounds called Cytokine Release Inhibitory Drugs (CRIDs) that inhibited the post-translat...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3245271?pdf=render |
id |
doaj-ed2df02dd6da4d1aa07f6cc150804fbc |
---|---|
record_format |
Article |
spelling |
doaj-ed2df02dd6da4d1aa07f6cc150804fbc2020-11-24T22:25:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-01612e2953910.1371/journal.pone.0029539The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes.Rebecca C CollAvril RobertsonMark ButlerMatthew CooperLuke A J O'NeillThe Inflammasomes are multi-protein complexes that regulate caspase-1 activation and the production of the pro-inflammatory cytokine IL-1β. Previous studies identified a class of diarylsulfonylurea containing compounds called Cytokine Release Inhibitory Drugs (CRIDs) that inhibited the post-translational processing of IL-1β. Further work identified Glutathione S-Transferase Omega 1 (GSTO1) as a possible target of these CRIDs. This study aimed to investigate the mechanism of the inhibitory activity of the CRID CP-456,773 (termed CRID3) in light of recent advances in the area of inflammasome activation, and to clarify the potential role of GSTO1 in the regulation of IL-1β production.In murine bone marrow derived macrophages, CRID3 inhibited IL-1β secretion and caspase 1 processing in response to stimulation of NLRP3 and AIM2 but not NLRC4. CRID3 also prevented AIM2 dependent pyroptosis in contrast to the NLRP3 inhibitors glyburide and parthenolide, which do not inhibit AIM2 activation. Confocal microscopy and Western blotting assays indicated that CRID3 inhibited the formation of ASC complexes or 'specks' in response to NLRP3 and AIM2 stimulation. Co-immunoprecipitation assays show that GSTO1 interacted with ASC.These results identify CRID3 as a novel inhibitor of the NLRP3 and AIM2 inflammasomes and provide an insight into the mechanism of action of this small molecule. In addition GSTO1 may be a component of the inflammasome that is required for ASC complex formation.http://europepmc.org/articles/PMC3245271?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rebecca C Coll Avril Robertson Mark Butler Matthew Cooper Luke A J O'Neill |
spellingShingle |
Rebecca C Coll Avril Robertson Mark Butler Matthew Cooper Luke A J O'Neill The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS ONE |
author_facet |
Rebecca C Coll Avril Robertson Mark Butler Matthew Cooper Luke A J O'Neill |
author_sort |
Rebecca C Coll |
title |
The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. |
title_short |
The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. |
title_full |
The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. |
title_fullStr |
The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. |
title_full_unstemmed |
The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. |
title_sort |
cytokine release inhibitory drug crid3 targets asc oligomerisation in the nlrp3 and aim2 inflammasomes. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2011-01-01 |
description |
The Inflammasomes are multi-protein complexes that regulate caspase-1 activation and the production of the pro-inflammatory cytokine IL-1β. Previous studies identified a class of diarylsulfonylurea containing compounds called Cytokine Release Inhibitory Drugs (CRIDs) that inhibited the post-translational processing of IL-1β. Further work identified Glutathione S-Transferase Omega 1 (GSTO1) as a possible target of these CRIDs. This study aimed to investigate the mechanism of the inhibitory activity of the CRID CP-456,773 (termed CRID3) in light of recent advances in the area of inflammasome activation, and to clarify the potential role of GSTO1 in the regulation of IL-1β production.In murine bone marrow derived macrophages, CRID3 inhibited IL-1β secretion and caspase 1 processing in response to stimulation of NLRP3 and AIM2 but not NLRC4. CRID3 also prevented AIM2 dependent pyroptosis in contrast to the NLRP3 inhibitors glyburide and parthenolide, which do not inhibit AIM2 activation. Confocal microscopy and Western blotting assays indicated that CRID3 inhibited the formation of ASC complexes or 'specks' in response to NLRP3 and AIM2 stimulation. Co-immunoprecipitation assays show that GSTO1 interacted with ASC.These results identify CRID3 as a novel inhibitor of the NLRP3 and AIM2 inflammasomes and provide an insight into the mechanism of action of this small molecule. In addition GSTO1 may be a component of the inflammasome that is required for ASC complex formation. |
url |
http://europepmc.org/articles/PMC3245271?pdf=render |
work_keys_str_mv |
AT rebeccaccoll thecytokinereleaseinhibitorydrugcrid3targetsascoligomerisationinthenlrp3andaim2inflammasomes AT avrilrobertson thecytokinereleaseinhibitorydrugcrid3targetsascoligomerisationinthenlrp3andaim2inflammasomes AT markbutler thecytokinereleaseinhibitorydrugcrid3targetsascoligomerisationinthenlrp3andaim2inflammasomes AT matthewcooper thecytokinereleaseinhibitorydrugcrid3targetsascoligomerisationinthenlrp3andaim2inflammasomes AT lukeajoneill thecytokinereleaseinhibitorydrugcrid3targetsascoligomerisationinthenlrp3andaim2inflammasomes AT rebeccaccoll cytokinereleaseinhibitorydrugcrid3targetsascoligomerisationinthenlrp3andaim2inflammasomes AT avrilrobertson cytokinereleaseinhibitorydrugcrid3targetsascoligomerisationinthenlrp3andaim2inflammasomes AT markbutler cytokinereleaseinhibitorydrugcrid3targetsascoligomerisationinthenlrp3andaim2inflammasomes AT matthewcooper cytokinereleaseinhibitorydrugcrid3targetsascoligomerisationinthenlrp3andaim2inflammasomes AT lukeajoneill cytokinereleaseinhibitorydrugcrid3targetsascoligomerisationinthenlrp3andaim2inflammasomes |
_version_ |
1725756550302138368 |